The abstract is read at the publisher; the summary is JClub's.
Vascular smooth muscle cell–derived osteoprotegerin drives pulmonary arterial hypertension in the SuHx mouse model, and VSMC-specific OPG deletion improves haemodynamics.
- Why it matters: The cellular source of pathogenic OPG and how anti-OPG therapy blocks PAH were unclear, limiting targeted mechanistic understanding.
- What they did: Conditional Tnfrsf11b deletion was induced by tamoxifen in multiple lineages in OPGfl/fl mice, with PAH induced by Sugen5416/hypoxia; kinase profiling (PamStation) and IPAH-PASMC experiments tested PI3K-Akt and AKT1.
- The result: Only smMHCcretg/0/OPGfl/fl mice showed significantly improved right ventricular systolic pressure and pulmonary vascular resistance, while anti-OPG antibody reduced AKT phosphorylation in IPAH-PASMCs and AKT1 knock-down reduced OPG-driven proliferation and migration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.